3SOF

That's no g.

2005-10-31 08:00:04 

NanoViricides Has Begun Preclinical Studies For Their First Anti-Viral Drug Targeted Against Bird Flu; Studies Are Being Conducted at the Beth Israel Deaconess Medical Center, a Teaching Hospital of Harvard Medical School 


WEST HAVEN, Conn.--(BUSINESS WIRE)--Oct. 31, 2005--
NanoViricides, Inc. (Pink Sheets:NNVC), today announced
that it has commenced preclinical studies for its anti-viral drug
FluCide-I(TM). The studies are being conducted at the Beth Israel
Deaconess Medical Center, a teaching hospital of Harvard Medical
School, under the direction of Dr. Krishna Menon. Dr. Menon, the
Company's Chief Regulatory Officer, explained that nanoviricides are
complex materials. "We have started working on the basic safety of the
polymer under a maximum tolerated dose protocol in mice. In the second
part we will study the ligands that target FluCide-I(TM) to H5N1 and
common influenza viruses. Thereafter, we will study the efficacy of
FluCide-I(TM) itself against H5N1 and common influenza."
Dr. Anil Diwan, President, explained that, "if successful, the
relevance of nanoviricides can be compared to the discovery of
Penicillin, the very first bactericide. Prior to antibiotics,
bacterial infections were treated with patient isolation, chicken soup
and Vitamin C. Current anti-viral medicines can at best only partially
inhibit the virus from multiplying in the human body. Although we
cannot make claims of certainty yet, after we get good results from
these studies we will be able to say that we have developed a true
virus killer."
The Company is encouraged by the recent statements from high level
international officials and health ministers of different countries
concerning the urgency of developing effective vaccines and treatments
and believes that a rapid regulatory approval of FluCide-I(TM), is
possible should these studies be successful.

http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is
creating special purpose nanomaterials for viral therapy. A
NanoViricide(TM) is a specially designed, flexible, nanomaterial that
contains an encapsulated active pharmaceutical ingredient and targets
it to a specific type of virus, like a guided missile.

Moving today......   

NANOVIRICIDES INC (Other OTC:NNVC.PK) Delayed quote data 

Last Trade: 0.74
Trade Time: 12:55PM ET
Change:  0.16 (27.59%)
Prev Close: 0.58
Open: 0.61
Bid: N/A
Ask: N/A
1y Target Est: N/A

  Day's Range: 0.61 - 0.85
52wk Range: N/A
Volume: 520,200
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)

Looks like it may be time to start buying again...

The best entry is near the LT blue upsloping support line... eyeing the chart this comes to .65-.70 

1) Touched LT upsloping trendline
2) Hammer Candle
3) Near Horizontal Support Level (Support 1)
4) Flu stocks may be ready to run again....

Other input appreciated. NNVC bottoming??? What do you guys think?

Thanks,
Cal

Sitting at .98

Would wait for a pullback to enter... (.65-.70) would represent the best price.

Taking a deeper look into NNVC - Low float high spread  - could be big once the flu scare comes back...

NNVC facing double resistance at just over 1.00

Upsloping and horizontal resistance trendlines converge at just over1.00

Seems to be sitting fine at and around 1.00 with a pop to 1.1  I also believe the flu scare will come back and push these guys along with others in the area higher.  Good potential here; I also drew the same bottom trend support line as you did so a retrace would be in order for a proper entry. 

-rcr-

NNVC creating a small symmetrical triangle formation. Watch to see which way NNVC breaks out of this triangle....

cal 

Quote from: poorman1 on October 05, 2005, 10:52:12 AM
I don't recommend buying such speculative issues, but simply pointing out some of the alternative stocks in the Avain flu area.

Breakout.......Symmetrical Triangle (continuation) Pattern
You don't recommend buying such speculative issues poorman1!!!!
But look what this little pup did.
A great pick .......Outstanding! I Applaud you many times over.....

Technicals
Record Price High
Most Actives
Record Price Break Out
Stochastic - Bearish
Percentage Gainer

Last Price Quote is:
55.54%above 13-day EMA
133.46%above 50-day EMA

caught on the sidelines on this one, hoped you made out well.

moving on up today....
+36.99%.......Volume @........2,880,098

Press Release Source: NanoViricides, Inc.


NanoViricides Collaborates with Vietnam Government to Develop Drug To Treat Bird Flu Virus
Monday January 9, 8:00 am ET 
Company to receive H5N1 (Avian Flu) biologics from Vietnam


WEST HAVEN, Conn.--(BUSINESS WIRE)--Jan. 9, 2006--NanoViricides, Inc. (Pink Sheets: NNVC - News) announced today the results of the company's recent trip to Vietnam.


Company officials met with senior officials in the Ministry of Health which resulted in the signing of Memoranda of Understanding (MOU) with governmental agencies responsible for the prevention and treatment of the H5N1 virus. The MOU calls for the government to supply biological materials to Nanoviricides, Inc., which are needed to rapidly develop a drug treatment for avian flu (AviFluCide-I(TM)). The Company believes that other than the US Centers for Disease Control and an international organization based in Europe, no other government or company has been granted access to certain of these biologics.

"Our approach is virus-specific therapy. Having unique access to the H5N1 virus enables us to develop drugs that act directly against this particular virus, whereas other companies are developing drugs against common influenza virus and hoping that some of them may also work against H5N1," said Dr. Anil Diwan, President of Nanoviricides.

Terms of the MOU also call for the collaborative development of a treatment for rabies, a generally fatal disease. The MOU allows these governmental agencies to have an exclusive license to use these drugs for the Vietnamese market.

Eugene Seymour, MD, MPH, CEO of Nanoviricides, Inc., says, "The MOU with Vietnam is a landmark agreement. It will enable Nanoviricides, Inc. to pursue its goal of having AviFluCide-I(TM) tested in overseas facilities, because the company now has access to the current H5N1 strain of the virus. Our operational plan calls for testing to be completed in the next twelve weeks." Dr. Seymour added, "Our system is also perfectly suited to deal with certain potential bioweapon viruses such as Ebola and Marburg. To our knowledge, we have a major head start in the area of targeted anti-viral therapies.

Other Company news:

The Company has issued a "stop transfer" on approximately 3.8 million shares and options held by a former officer and the individuals involved with the "shell company" Edotcom.com, prior to its merger with NanoViricides. The Company will be seeking official and judicial relief as well as seek monetary damages for the harm caused to the Company. The Company will update its shareholders in a separate press release on this matter to be released within the coming days. These actions will help the Company complete its audit and become a reporting company. It is management's goal to meet the requirements necessary to be listed on a major exchange.

ABOUT NANOVIRICIDES, INC.

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for anti-viral therapy. A nanoviricide(TM) is a specially designed, flexible, nanomaterial with or without an encapsulated active pharmaceutical ingredient and a targeting ligand to a specific type of virus, like a guided missile.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.


Contact:
NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
[email protected]

--------------------------------------------------------------------------------
Source: NanoViricides, Inc.

Man this one is really movin, I traded this previously from .36 to 1.00. Would of been nice to still have it now

-fousc

Another Big Day......

Volume: 3,557,975
Avg Vol (3m): N/A

Today a White Closing Marubozu was formed. This shows that the day opened and then prices went lower slightly, however it was followed by a rally that drove the prices over the opening price and the rally continued all day ending with a closing price equal to the high of the day.

Technicals
Record Price High
Gap Up
Percentage Gainer

Last Price Quote is:
117.33%above 13-day EMA
236.27%above 50-day EMA

A message that I have service for on NNVC
Another strong day from NanoViricides (Pink Sheets: NNVC) , which added 45% on heavy volume of 3.5 million shares. Months back in Sleuth ("Two Tales of One Company," Sept. 6, 2005), I talked about anchoring, one of the many mistakes we as human beings -- and investors -- make consistently:

"We anchor ourselves to short-cut problem-solving, looking upon new information as a piece of the puzzle of what we already 'know,' rather than reanalyzing the problem in its new entirety."

At its most basic, as I've written in the past, all investment decisions are bets. Thus, the question is: Would I bet $2.13 -- the current price -- on this company, if I were "reanalyzing the problem in its new entirety" -- i.e., looking at it -- and the people behind it -- with fresh eyes, as if for the very first time. Well, I did that, and if I'm to be completely honest -- and can somehow put aside its robust performance thus far -- the fact is I would pay $2.13 for this stock. I might regret not having found it earlier, but at a couple, three dollars, it would be an easy bet for me.

If I'm to be completely fair in taking a stab at some kind of initial price target for NNVC, and base that target on a comparison to BioCryst, I really should back out BioCryst's recent deal with Roche, which is probably worth $150 million or so of its market cap. The resultant adjusted market value would be in the neighborhood of $300-320 million. For NanoViricides, that would mean a share price of $3-3.20. It's at that point that I might call NNVC a "hold" instead of a "buy."